During a period of upheaval among non-alcoholic steatohepatitis (NASH) R&D competitors, Akero Therapeutics Inc. may be emerging from the middle of the pack with follow-up histology data from its successful Phase IIa study of efruxifermin (EFX/AKR-001) that shows antifibrotic and NASH-resolution effects better than seen in clinical trials for competing drugs.
The expected order in NASH clinical development has overturned in recent weeks, with Genfit SA’s Phase III miss for...